Dilbert Creator Scott Adams Urges Trump to Force Kaiser to Deliver Life-Saving Cancer Drug Amid Rapid Decline

Scott Adams, the 68-year-old creator of Dilbert, says he is in rapid decline from metastatic prostate cancer.

“President Donald Trump is lending a hand to help save the life of “Dilbert” comic strip creator Scott Adams, he wrote on social media Sunday”

CNN

He is urgently seeking Pluvicto, an FDA-approved IV radioligand therapy, after his provider Kaiser Permanente Northern California approved but then delayed scheduling his infusion.

CNN

He publicly appealed to former President Donald Trump for help.

Robert F. Kennedy Jr. also responded offering assistance.

Coverage varies in emphasis: Western mainstream outlets stress the health crisis and approval-versus-delay.

Western alternative outlets underscore the political intervention angle.

Asian coverage adds technical detail about Pluvicto’s mechanism and indication.

Political and influencer intervention has accelerated the story’s visibility.

Daily Caller reports that Trump is 'on it' and that Dan Scavino said Trump, RFK Jr., and Dr. Oz were monitoring the situation.

Daily Mail

The San Francisco Standard highlights the viral reach of Adams’ posts and support from figures like Bill Pulte, Pat Soon-Shiong, and Naval Ravikant.

The Post Millennial adds that Adams skipped his show to go to the ER and argued Trump is the only candidate who would 'bend the rules' to help.

Just the News gives a stripped-down account noting Adams plans to ask Trump for assistance after a prior offer to help.

Some outlets widen the political frame in different directions.

“(Photo by Kent Nishimura/Getty Images) Scott Adams asked President Donald Trump on Sunday to intervene with his health insurance provider after it failed to schedule a potentially life-saving cancer treatment”

dailycaller

Букви reports that Adams said he would contact President Joe Biden to intervene, even as it also notes Trump’s willingness to help and RFK Jr.’s support, and it invokes Trump’s Right to Try Act.

Daily Mail similarly situates Adams’ diagnosis alongside Biden’s own prostate cancer announcement.

By contrast, Fox News centers Trump’s potential role in expediting treatment.

A singular report from World Tribune claims Adams is now scheduled for treatment on November 3, 2025 and had previously said his life expectancy was limited to summer 2025—details not found elsewhere and that sit uneasily with the sense of immediate urgency.

Media framing diverges on Adams’ public persona.

Fox News notes reactions from commentators to Adams’ previously alleged racist remarks.

Fox News

Hindustan Times recaps his history of political predictions, some later listed among Politico’s 'worst predictions.'

The Post Millennial underscores his identity as a Trump supporter and includes his own provocative claim that Trump would 'bend the rules.'

Daily Caller focuses on the details of the access dispute and rapid decline without highlighting past controversies.

Across outlets, the core access issue remains consistent: Adams says Kaiser Permanente Northern California approved Pluvicto but has not promptly scheduled the short IV infusion he believes could extend his life.

Local and international sources frame this as emblematic of broader barriers to life‑saving drugs.

Hindustan Times

The San Francisco Standard details insurance hurdles and outsized online attention.

Букви underscores the challenge of accessing costly medicines.

Hindustan Times and Daily Mail stress the scheduling mishap and Adams’ rapid decline.

The throughline is Adams leveraging public pressure and political connections to accelerate care.